Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study.
about
Novel biological markers of bone: from bone metabolism to bone physiologyMolecular Abnormalities Underlying Bone Fragility in Chronic Kidney Disease.Parathyroid hormone: anabolic and catabolic actions on the skeletonSerum sclerostin in high-activity adult patients with juvenile idiopathic arthritis.Circulating sclerostin associated with vertebral bone marrow fat in older men but not womenMarrow fat and bone: review of clinical findings.Increased sclerostin levels after further ablation of remnant estrogen by aromatase inhibitors.Plasma Sclerostin in HIV-Infected Adults on Effective Antiretroviral Therapy.Has sclerostin a true endocrine metabolic action complementary to osteocalcin in older men?Independent association between serum sclerostin levels and carotid artery atherosclerosis in prevalent haemodialysis patients.Sclerostin serum levels in patients with systemic autoimmune diseasesSclerostin as a novel marker of bone turnover in athletes.Serum Sclerostin Levels in Patients with Human Immunodeficiency Virus Infection and Their Association with Bone Turnover Markers and Bone Mineral DensitometrySclerostin and bone strength in women in their 10th decade of life.Serum sclerostin levels in renal cell carcinoma patients with bone metastasesCirculating sclerostin levels and markers of bone turnover in Chinese-American and white women.Sclerostin is positively associated with bone mineral density in men and women and negatively associated with carotid calcified atherosclerotic plaque in men from the African American-Diabetes Heart Study.Clinical utility of serum sclerostin measurements.Effect of supplemental vitamin D and calcium on serum sclerostin levels.The role of Wnt signaling and sclerostin in the pathogenesis of glucocorticoid-induced osteoporosis.Novel assessment tools for osteoporosis diagnosis and treatment.Vitamin D and spondyloarthritis.The Utility of Biomarkers in Osteoporosis Management.Hormonal and systemic regulation of sclerostin.Higher serum sclerostin levels and insufficiency of vitamin D are strongly associated with vertebral fractures in hemodialysis patients: a case control study.The role of biochemical of bone turnover markers in osteoporosis and metabolic bone disease: a consensus paper of the Belgian Bone Club.Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: changes in bone turnover markers and circulating sclerostin levels.Serum sclerostin levels following treatment with parathyroid hormone.Higher circulating parathormone is associated with smaller and weaker bones in obese children.Sclerostin and chronic kidney disease: the assay impacts what we (thought to) know.24-hour profile of serum sclerostin and its association with bone biomarkers in men.Circulating levels of dickkopf-1, osteoprotegerin and sclerostin are higher in old compared with young men and women and positively associated with whole-body bone mineral density in older adults.Sclerostin in institutionalized elderly women: associations with quantitative bone ultrasound, bone turnover, fractures, and mortality.The relationship between postmenopausal women's sclerostin levels and their bone density, age, body mass index, hormonal status, and smoking and consumption of coffee and dairy products.Decreased Plasma Levels of Sclerostin But Not Dickkopf-1 are Associated with an Increased Prevalence of Osteoporotic Fracture and Lower Bone Mineral Density in Postmenopausal Korean Women.Sclerostin Expression in Bile Ducts of Patients With Chronic Cholestasis May Influence the Bone Disease in Primary Biliary Cirrhosis.Association of circulating dipeptidyl-peptidase 4 levels with osteoporotic fracture in postmenopausal women.Bone Turnover Status: Classification Model and Clinical Implications.Methylation of BoneSOST, Its mRNA, and Serum Sclerostin Levels Correlate Strongly With Fracture Risk in Postmenopausal WomenAssociation of Wnt Inhibitors, Bone Mineral Density and Lifestyle Parameters in Women with Breast Cancer Treated with Anastrozole Therapy
P2860
Q28067712-0175F3DD-782A-46FF-8A2B-F503DA51636AQ30234751-7D41DFCF-DC8E-4C5B-8F03-34AA4D3A0681Q33609126-FE11A11B-C42E-4277-9492-CE1AD2DEE57EQ34537434-0BAD512A-12AE-448A-8FA4-F8128FCA5641Q34628276-1AAD7A9D-C9AB-4E0A-B881-D66044D631A6Q35229131-C0AA7C2B-0DF6-47BA-932E-03B784C23F54Q35260816-C5DEED7C-CEAE-4AD4-A26D-0B2585247659Q35861519-CD1A334D-9B7C-4777-A683-B71A96A64B97Q35967442-837CD8F2-B757-47FE-B901-7ADC246C344EQ36306725-9972369A-6B18-4CAB-83DE-15F09A9ABF0FQ36561360-5C5FD8CB-6074-40B7-9C64-16C1C68639F4Q36606834-95773DB2-F36C-4086-9267-CD4A35F500F6Q36685956-02E27F0C-E2FC-4CF6-8D1C-C49BF9349BE7Q37045961-DC269F2A-A47A-4122-BEC8-2D9C14154582Q37282121-BF60AC28-3055-4607-A281-EED2A36AF7ECQ37361795-0E262BED-66A8-4EF8-B73F-3160815C0725Q37428965-1F5E1D31-FC67-446E-9D6D-2D9191A75C0DQ37605570-C0AB9C1A-0D17-427D-906C-0DF09F150D58Q37682879-695D1CCF-6953-44FB-93F9-B244917DCFC3Q38184470-63A7F902-CCF1-4D12-ACE5-955A585BF9F1Q38216229-FEC71552-C6FF-45BD-B22A-90F925791297Q38262855-0718B108-4CB6-431B-82A1-AD00D23FEC95Q38921875-5AA8817B-7AD9-42D5-8EB7-C009A28BA5C6Q39037907-D5F9D3DD-0338-4027-B485-19596B01E78DQ39342144-3715FDE6-7258-45A8-A7EB-DBB880A2A51EQ40828040-B6C7670A-5279-4CEA-A5A8-F71207C8FE49Q41432679-CBF100D9-761A-487E-9E7A-8DB6AF888311Q44699083-9C729F60-878A-4F8C-BD10-A4F33321AF66Q45340912-C5B28D01-5A4D-4F40-83A9-AEE8A1631B12Q47630210-A839B248-33CC-4E84-B1C1-064E723C24FBQ47704837-36B969AE-669E-4F6C-A2B4-9085FA424550Q47740614-4449680F-20BD-47C5-8147-92BEFBFF8698Q51142825-AF3107F6-3E2D-4CE9-A4FE-781DA280290BQ51161134-DED08B96-9F7B-4A50-BE38-42229DFAA1EBQ51707392-93C87DFB-EFD9-4E8B-BEB6-0A92B1BCFFE5Q53137198-F5819911-6AFE-4920-9186-6B83876108F4Q54453132-FE16C458-D037-411C-B247-5604E6EF3817Q55002406-688D96B4-D90A-4B1D-B220-5DFC60A7DE8EQ57250831-D9875CA7-0297-448A-B8FD-851AD65D6EF5Q58730332-624055AD-B901-40F9-A4A6-794715B5C791
P2860
Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Association of serum sclerosti ...... pausal women: the OFELY study.
@en
Association of serum sclerosti ...... pausal women: the OFELY study.
@nl
type
label
Association of serum sclerosti ...... pausal women: the OFELY study.
@en
Association of serum sclerosti ...... pausal women: the OFELY study.
@nl
prefLabel
Association of serum sclerosti ...... pausal women: the OFELY study.
@en
Association of serum sclerosti ...... pausal women: the OFELY study.
@nl
P2093
P2860
P1476
Association of serum sclerosti ...... opausal women: the OFELY study
@en
P2093
P2860
P2888
P304
P356
10.1007/S00198-012-1978-X
P407
P577
2012-04-14T00:00:00Z
P6179
1024474928